In a sign that it is still struggling as competition emerges for it major drugs Procrit and Risperdal and that its stent business is still troubled by safety concerns, Johnson & Johnson (JNJ) announced that it would buy back as much as $10 billion of its shares.
JNJ has a market cap of $186 billion. The announcement did not move the shares much. They inched up 1.5% to $63, and are down about 6% this year.
With 2006 revenue of $53 billion, its is a bit surprising that JNJ is not using the capital to buy another company. It is hard not to imagine that it pharma business could not benefit from the R&D at one or more of its smaller biotech partners.
But, it’s only $10 billion.
Douglas A. McIntyre
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
